Denmark And San Diego

HOERSHOLM, Denmark and SAN DIEGO, September 7, 2011 - Santaris Pharma A/S provides update on the development of miravirsen, a microRNA-targeted drug inhibiting miR-122, which is currently in Phase 2 clinical trials to treat patients infected with the Hepatitis C virus (HCV) Scientists at Santaris Pharma A/S demonstrate specificity of "tiny" 8-mer LNA-based compounds, which have shown to successfully inhibit entire microRNA families providing potential new approach for treating cancer, viral infections, cardiovascular and muscle diseases Data presented by scientists at Santaris Pharma A/S demonstrate successful "naked" delivery uptake of LNA-based compounds, a key advantage over other RNA-based technologies that require complex delivery vehicles Versatility of the LNA Drug Platform allows Santaris Pharma A/S to develop both microRNA and mRNA-targeted drugs with excellent specificity and increased affinity to drug target, providing improved potency and favorable tissue-penetrating properties Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced advancements from the company's RNA-targeted research programs utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform.

HOERSHOLM, Denmark and SAN DIEGO, May 11, 2011 - Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

HOERSHOLM, Denmark and SAN DIEGO, May 4, 2011 - -- Phase 1 clinical study to assess safety and tolerability of SPC5001, a RNA-targeted drug inhibiting PCSK9, which is a protein involved in removing low-density lipoprotein cholesterol (LDL-C) or "bad" cholesterol from the bloodstream -- In a study representing 147 million people, the World Health Organization recently reported that most patients with high cholesterol levels are not getting the treatment they need to reduce their risk of cardiovascular diseases such as heart attack and stroke -- Data from preclinical studies showed that SPC5001 provided fast-acting, potent and long-lasting inhibition of PCSK9 and reductions in LDL-C by up to 74% -- Developed using Santaris Pharma A/S Locked Nucleic Acid Drug Platform, SPC5001 is one of the drugs in the company's multi-faceted cardiometabolic program aimed at helping patients gain better control of their target cholesterol levels Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced SPC5001 into Phase 1 clinical trials for the treatment of high cholesterol.

HOERSHOLM, Denmark and SAN DIEGO, March 21, 2011 - A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families.

HOERSHOLM, Denmark and SAN DIEGO, February 28, 2011 - Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital (MGH) for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.